H. Lundbeck is a pharmaceutical company specialized in neuroscience, focusing on the research, development, manufacturing, and commercialization of treatments for brain diseases. The company operates globally, with its products present in numerous countries and operations in multiple nations. Its main markets include the United States, China, Spain, Canada, Italy, France, Australia, Brazil, South Korea, and the United Kingdom. H. Lundbeck maintains production facilities in Denmark, France, and Italy, alongside research and development centers in Denmark, Asia, and the United States. The company was founded by Hans Lundbeck in Copenhagen in the early 20th century and is majority-owned by the Lundbeck Foundation.

Summarised from the company's own disclosures, fiscal year ended Oct 2026

Industry Drug Manufacturers - Specialty & Generic Homepage lundbeck.com
Sector Healthcare IR page lundbeck.com/global/investors
Tags
neuroscience, brain diseases, pharmaceuticals, central nervous system, psychiatry, neurology, Lundbeck, H. Lundbeck A/S, Lundbeck Foundation, Lundbeckfond Invest A/S, Progress in Mind
Press page —

Metrics

Valuation  
Market cap —
Market cap (USD) —
P/E 18.76
PEG 1.01
P/BV —
P/S —
P/OCF —
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE 12.8%
ROI 8.8%
ROIC 14.6%
Profit margin 13.0%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y —
Earnings growth 3y (net profit CAGR) 18.5%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock —
Diluting (TTM) —
Debt/Equity 44.9%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score —
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Revenue 24.63B 22.004B 19.912B 18.246B 16.299B
Net profit 3.192B 3.143B 2.29B 1.916B 1.318B

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

News

English

Changes to the Board of Directors of H. Lundbeck A/S

Sun, Oct 18, 2026 17:54 CET Report this content

  • Dorothea Wenzel, Chair of the Board, has informed the Board that she will step down in connection with the Annual General Meeting in 2027. 
  • Following the AGM, Lundbeck’s Board intends to appoint Lars Fruergaard Jørgensen as the new Chair.  
  • Effective 10 November 2026, Lars Fruergaard Jørgensen will join the Board as an observer, until the formal election. 

H. Lundbeck A/S (Lundbeck) announces that Dorothea Wenzel has informed Lundbeck’s Board of Directors (Board) that she will step down in connection with the Annual General Meeting (AGM) in 2027. Dorothea joined the Lundbeck Board in 2021 where she served as Chair of the Audit Committee until she was appointed as the Chair of the Board following the AGM in March 2025.  

The proposed change in Board leadership comes as Lundbeck prepares to enter the next phase of its Focused Innovator strategy. Over the past three years, the company has undergone a significant transformation, strengthening its commercial performance, advancing its pipeline and building a stronger foundation for the future. The upcoming Scale phase of the strategy will focus on translating these achievements into sustainable long-term growth. 

The Board intends to elect Lars Fruergaard Jørgensen to succeed Dorothea Wenzel as Chair of the Board. Effective 10 November 2026, Lars will join the Board as an observer until the AGM 2027, at which time he is expected to be formally elected as member of the Board, subject to shareholder approval.  

Lars Fruergaard Jørgensen is an accomplished pharmaceutical executive with more than 30 years of international experience in the healthcare industry. He served as President and Chief Executive Officer of Novo Nordisk from 2017 to 2025, following a distinguished career in senior leadership positions across the company's global organization. 

During his tenure as CEO, he led Novo Nordisk through a period of significant growth and transformation, strengthening its global leadership in diabetes care and establishing a leading position in obesity treatment. 

He brings extensive expertise in global pharmaceutical strategy, innovation, commercialization, and organizational transformation. He has also served as President of the European Federation of Pharmaceutical Industries and Associations (EFPIA). He currently chairs the Board of Directors of Healthcare Denmark and is a member of the Board of Directors of Danmarks Nationalbank. He holds an MSc in Finance and Business Administration from Aarhus University. 

Lene Skole, Vice Chair, said: 
“On behalf of the Lundbeck Foundation and the entire Board of Directors of Lundbeck, I would like to thank Dorothea for her commitment and dedication over the past five years. She has been part of the entire transformation period in different roles at Board level, including the appointment of a new CEO in 2023 followed by the launch of Lundbeck’s Focused Innovator strategy in February 2024. Lundbeck is in a very different and much stronger position today than just a few years ago. This is a natural moment to look ahead and ensure continuity in the leadership of the Board as we enter the next phase of our journey. I am confident that Lars Fruergaard Jørgensen will bring valuable experience and perspectives to the role, supporting Lundbeck's continued development and long-term ambitions.” 

Dorothea Wenzel, Chair of the Board, said: 
“It has been an honor and a privilege to serve as the Chair of the Board of Directors of Lundbeck. Lundbeck is a remarkable company, and I am proud of the development the company has undertaken in recent years. Together with the Board, management and our dedicated employees, we have made important progress in strengthening the company and positioning it for long-term growth over the past five years. As Lundbeck prepares to enter the next phase of its strategy, I believe this is a natural time to pass on the responsibility of leading the Board. I am confident in the company's direction and its ability to build on the strong foundation we have established.” 

Lars Fruergaard Jørgensen said: 
“I am excited by the prospect of chairing Lundbeck at such a pivotal moment. Lundbeck has built a strong foundation in brain health, with a successful business, a solid balance sheet, and a pipeline with significant late-stage potential. The company has the strength and momentum to step into its next phase of growth. I look forward to the opportunity to support that ambition, together with the Board and the executive leadership team, for the benefit of patients, employees and shareholders.” 

The nominated candidates for the Board of Directors will be included in the notice convening the AGM 2027. 

English

Lundbeck presents Phase Ib data for Lu AF28996 in advanced Parkinson’s disease, as Phase II trial begins

Tue, Oct 06, 2026 08:00 CET Report this content

  • Results from an 18-week, open-label Phase Ib trial of investigational Lu AF28996 in people with advanced Parkinson’s disease are being presented at MDS 2026
  • The trial provided initial safety and tolerability data for Lu AF28996, with most treatment-emergent adverse events reported as mild
  • Descriptive changes from baseline in motor fluctuations were observed with Lu AF28996, including increases in Good ON-time and reductions in OFF-time, alongside reductions in dyskinesia severity
  • Phase II development of Lu AF28996 is underway, with the first patient randomized in the DARE2 trial¹

Valby, Denmark, Tuesday 6 October 2026 – H. Lundbeck A/S (Lundbeck) today announced results from an open-label Phase Ib trial evaluating Lu AF28996, a novel, investigational, oral prodrug of D1-like/D2-like dopamine receptor agonist, in people with advanced Parkinson’s disease experiencing motor symptoms sub-optimally controlled despite optimized non-invasive antiparkinsonian medication. The results are being presented at the International Congress of Parkinson’s Disease and Movement Disorders® (MDS) 2026 in Seoul, South Korea.

Parkinson’s disease is characterized by the progressive degeneration of dopamine-producing neurons in the brain.2 While levodopa remains the cornerstone of symptomatic treatment, many people experience difficult-to-manage motor complications as the disease progresses.3,4 These include fluctuations between periods of good symptom control (“ON-time”) and periods when symptoms return or worsen (“OFF-time”), and treatment-related dyskinesia (involuntary movements) despite optimized treatment.3 For people with advanced Parkinson’s disease, many treatment options involve invasive procedures or continuous drug delivery, requiring patients to meet specific eligibility criteria.4,5 There remains a need for effective, well-tolerated and non-invasive treatment approaches that can provide more consistent motor control.

“Many people with advanced Parkinson’s disease continue to experience motor fluctuations and dyskinesia that can significantly affect daily life,” said Tarek Samad, Executive Vice President and Head of Research & Development at Lundbeck. “We are encouraged by the Phase Ib results with Lu AF28996, including the improvements observed alongside substantial reductions in levodopa dose. With the DARE2 Phase II trial now underway, we are taking the next step in evaluating its potential in a larger, randomized and controlled study.”

Phase Ib results
NCT04291859 comprised Part A once- and twice-daily ascending-dose cohorts and Part B twice-daily cohorts B1–B3. The MDS 2026 presentation and this release report results from Part B. In Part B of the trial, 34 participants received Lu AF28996 twice daily for six weeks.6 Eligible participants could continue in an optional extension period of up to 12 additional weeks, and 25 participants elected to enter the extension.

During the trial, most treatment-emergent adverse events were considered mild. No unexpected safety signals were observed, and the safety profile was consistent with a dopaminergic mechanism of action of Lu AF28996. The most common treatment-emergent adverse events were nausea, dizziness, and falls.

At baseline, participants experienced a mean of 9.5 hours of Good ON-time (ON-time without troublesome dyskinesia), 4.7 hours of OFF-time, and 1.8 hours of ON-time with troublesome dyskinesia per day. At Weeks 6 and 18, respectively, Good ON-time increased from baseline by 3.6 and 3.4 hours, OFF-time decreased by 2.3 and 2.0 hours, and ON-time with troublesome dyskinesia decreased by 1.2 and 1.4 hours.

These changes were accompanied by reductions from baseline in dyskinesia severity, as measured by the Unified Dyskinesia Rating Scale (UDysRS) total score, of 8.5 points at Week 6 and 14.5 points at Week 18, from a baseline score of 28.3 points. Reductions in mean daily levodopa dose were observed, with reductions of 53.4% at Week 6 and 29.2% at Week 18.

Among participants with ≥1 hour/day of troublesome dyskinesia at baseline, mean changes from baseline in daily ON-time with troublesome dyskinesia were −2.3 hours per day at Week 6 and −2.8 hours at Week 18.

The trial was exploratory, involved a limited number of participants and did not include a placebo or active comparator. The findings are to be further explored in the larger, randomized and controlled DARE2 trial.

The Phase II DARE2 trial
DARE2 (NCT07514858) is a Phase II randomized, double-blind, parallel-group, placebo-controlled, flexible-dose trial evaluating Lu AF28996 in approximately 150 adults with Parkinson’s disease who continue to experience motor fluctuations despite optimized non-invasive symptomatic treatment.1 The primary endpoint is change from baseline to Week 19 in daily Good ON-time.1

The first participant in DARE2 has been randomized, and recruitment is underway at selected sites in the United States. Additional sites are planned in the United Kingdom, Spain, Italy, Germany, France, Poland, the Czech Republic, Sweden and Japan. Current site information is available on ClinicalTrials.gov .1

Lu AF28996 is not approved by the US Food and Drug Administration (FDA) or any other regulatory agency, and the efficacy and safety of Lu AF28996 have not been established.
 

About Parkinson’s disease
Parkinson’s disease (PD) is a progressive and disabling neurological disease characterized by motor symptoms including slowness of movement, tremor and rigidity, as well as a range of non-motor symptoms.4,5 There are currently no established treatments that modify the progression of PD, and levodopa remains a cornerstone of symptomatic treatment.2,4 With long-term levodopa treatment, many people develop motor complications, including periods when symptoms return or worsen (“OFF-time”) and dyskinesia (involuntary movements), which can significantly affect daily functioning and quality of life.2-5

PD is the second most common neurodegenerative disease after Alzheimer’s disease and the most common movement disorder.7,8 In 2021, an estimated 11.77 million people worldwide were living with PD, and its prevalence is projected to more than double by 2050.8,9 As PD progresses, functional independence can decline and reliance on caregivers and healthcare systems can increase, contributing to a substantial personal, societal and economic burden.

About Lu AF28996
Lu AF28996 is an investigational, novel and oral prodrug of a D1-like/D2-like dopamine receptor agonist, with a pharmacologic profile that may enhance dopaminergic striatal signaling in a prolonged manner. It is being investigated for its potential to improve motor fluctuations and levodopa-induced dyskinesia in people with Parkinson’s disease. Concerted activation of D1- and D2-like dopamine receptors may play an important role in motor control.10

Lu AF28996 is not approved by the US Food and Drug Administration (FDA) or any other regulatory agency, and the efficacy and safety of Lu AF28996 have not been established.
 

About NCT04291859
NCT04291859 was an open-label Phase Ib trial evaluating the safety, tolerability and clinical effects of Lu AF28996 in people with advanced Parkinson’s disease experiencing motor fluctuations, with or without dyskinesia, despite non-invasive antiparkinsonian medication.

Thirty-four participants received Lu AF28996 twice daily for six weeks, followed by an optional extension period of up to 12 weeks. Twenty-five eligible participants elected to enter the extension period.

The trial was exploratory, involved a limited number of participants and did not include a placebo or active comparator. The findings require confirmation in larger, randomized and controlled clinical trials.
 

English

Lundbeck to showcase progress across its movement disorders pipeline with data in multiple system atrophy and Parkinson’s disease at MDS® 2026

Fri, Oct 02, 2026 08:00 CET Report this content

  • Late-breaking Phase III MASCOT oral presentation will characterize the clinical profile and diversity of participants in Lundbeck’s ongoing global Phase III trial investigating amlenetug in multiple system atrophy (MSA)
  • New research across clinical trial endpoints, biomarkers, diagnostic tools and healthcare burden underscores Lundbeck’s expanding scientific program in MSA
  • Exploratory Phase Ib data for Lu AF28996 investigating difficult-to-treat motor complications in people with advanced Parkinson's disease

Valby, Denmark, 2 October 2026 – H. Lundbeck A/S (Lundbeck) today announced that data from its movement disorders pipeline will be presented at the International Congress of Parkinson’s disease and Movement Disorders® (MDS) 2026, taking place in Seoul, South Korea (4-8 October).

The presentations span MSA, a rare and rapidly progressing neurodegenerative disease, and advanced Parkinson’s disease (PD), where motor complications remain difficult to control despite optimized treatment. Together, the data reflect Lundbeck’s growing scientific focus in movement disorders and its commitment to advancing innovation in areas where significant unmet need remains.

A key highlight will be a late-breaking oral presentation describing the baseline characteristics of participants enrolled in MASCOT (NCT06706622), the ongoing Phase III trial of amlenetug in MSA. MASCOT enrolled 401 participants with clinically probable or clinically established MSA, including people with both MSA-C and MSA-P, representing a broad spectrum of people living with the disease. The trial is evaluating the safety and efficacy of amlenetug versus placebo over a 72-week double-blind treatment period, with results expected in Q3 2027.

“Movement disorders such as MSA and Parkinson’s disease remain among the most complex and high-need areas in neuroscience,” said Tarek Samad, Executive Vice President and Head of Research & Development at Lundbeck. “The breadth of research we are presenting at MDS reflects our commitment to advancing potential new medicines while strengthening the scientific understanding of the biomarkers and clinical tools needed to support progress for patients.”

Lundbeck will present additional research addressing important challenges in MSA clinical development. These include analyses supporting the use of the modified Unified Multiple System Atrophy Rating Scale Part I, or mUMSARS Part I, as a clinical trial endpoint designed to measure functional decline in people with MSA; validation of the Chinese version of UMSARS for use in clinical trials; and research into cerebrospinal fluid biomarkers that may support disease detection, differential diagnosis and monitoring.

The MSA program also includes new data highlighting the broader burden of MSA. A US observational database study found significantly higher healthcare costs and healthcare resource utilization among people with MSA compared with people with Parkinson’s disease, underscoring the intensive care requirements associated with this rapidly progressing disease.

Exploratory clinical data in advanced Parkinson’s disease
Lundbeck will also present new Phase Ib data for Lu AF28996, an investigational, novel, oral D1-like/D2-like dopamine receptor agonist being developed for people with advanced Parkinson’s disease experiencing motor complications.

The 18-week open-label Phase Ib trial evaluated safety, tolerability and clinical effects in people with inadequately controlled advanced PD experiencing motor fluctuations, with or without dyskinesia (involuntary movements).

The clinical findings will be complemented by preclinical data exploring the relationship between dose, motor efficacy and dyskinesia in a primate model of Parkinson’s disease (MPTP-macaque).

Lu AF28996 and amlenetug are investigational compounds and have not been approved for use by any regulatory authority. Their efficacy and safety have not been established.

Lundbeck’s scientific program at MDS:

Data presentations
Therapeutic  area Presentation content Presentation Type Details
Multiple system atrophy (MSA)Amlenetug ​MSA CSF Biomarker Identification: Identification of Candidate Cerebrospinal Fluid Biomarkers in Multiple System Atrophy Using Mass Spectrometry Based Proteomics in CSF Biobank Samples De novo; ePoster (121): Presenter:Pekka Kallunki 4 Oct 13:00-14:00 KST  Hall D, Station 2 Presentation order: 1
Multiple system atrophy (MSA)Amlenetug MSA US Healthcare Resource Utilization​: Healthcare Resource Utilization and Costs of Multiple System Atrophy in the United States: An Observational Database Study De novo; ePoster      (243): Presenter:Amar Mehta 4 Oct 12:00-13:00 KST  Hall D, Station 4 Presentation order: 1
Multiple system atrophy (MSA)Amlenetug Chinese UMSARS validation:Validation of the Chinese Version of the Unified Multiple System Atrophy Rating Scale De novo; ePoster      (150): Presenter:Anna Karin Berger 5 Oct 12:00-13:00 KST  Hall D, Station 4 Presentation order: 5
Multiple system atrophy (MSA)Amlenetug Modified UMSARS Psychometrics​:Psychometric Assessment of a Modified Version of the Unified Multiple System Atrophy Rating Scale Part I De novo; ePoster      (149): Presenter:Anna Karin Berger 5 Oct 12:00-13:00 KST  Hall D, Station 4 Presentation order: 4
Multiple system atrophy (MSA)Amlenetug MASCOT trial baseline characteristics​: Baseline characteristics of a Phase III double-blind, randomized trial of amlenetug for the treatment of multiple system atrophy Late breaker oral presentation; (OPP3): Presenter:Lotte Kjærsgaard 5 Oct 12:30-13:30 KST  Conference room E1Presentation order: 11
Multiple system atrophy (MSA)Amlenetug CSF α-Synuclein Assay to Differentiate MSA from PD​: A CSF C Terminal α Synuclein Assay to Differentiate Multiple System Atrophy From Parkinson’s Disease Oral presentation; (OPP3-G): Presenter:Pekka Kallunki 5 Oct 12:30-13:30 KST  Conference room E1Presentation order: 7
Parkinson’s disease Lu AF28996 Ph Ib Part B HLR: Lu AF28996, a Novel Oral D1-like/D2-like Receptor Agonist, Results from an 18-week open-label, Phase 1b Trial De novo; ePoster (732)Presenter:Alberto Cucca 6 Oct 09:30-10:30 KST  Hall D, Station 12 ​ Presentation order: 4
Parkinson’s disease Lu AF28996 Pre-clinical macaque data​: Oral D1-like/D2-like Receptor Agonist, Lu AF28996, Reduced Dyskinesia in the MPTP-Macaque Model De novo; ePoster (803) Presenter:Hanna Lindgren 6 Oct 09:30-10:30 KST  Hall D, Station 12 Presentation order: 3
Sponsored scientific symposium and forum presentation
Therapeutic area Title Speakers Details
Multiple system atrophy (MSA) Decoding MSA: From prodromal signs to clinical progression and integrative biomarkers Wassilios Meissner, Horacio Kaufmann Hirohisa Watanabe 5 Oct 12:15-13:15 KSTVenue: ASEM Ballroom 203, 2nd floor

 

About Multiple System Atrophy (MSA)
MSA is a rapidly progressing rare condition that causes damage to nerve cells in the brain. In a person with MSA, an abnormal build-up of the protein α-synuclein is thought to be responsible for damaging the areas of the brain that control balance, movement, and the body's normal functions.1 MSA is seriously debilitating and places a high disease burden on patients. There is currently no cure for MSA and no available treatment to slow its clinical progression.2

Symptoms of MSA usually start between 55 and 60 years of age, and the typical time to death is 8.6 years after symptom onset.2 Although there are many different possible symptoms of MSA, not everyone who is affected will experience all of them. The symptoms of MSA are wide-ranging and include muscle control problems, similar to those of Parkinson's disease.2 Many different functions of the body can be affected, and symptoms including urinary incontinence, frequent falling, and unintelligible speech occur within 3 years of disease onset. MSA is accompanied by reduced capacity to live independently, and death is often due to respiratory problems.

About amlenetug 
Amlenetug is a human monoclonal antibody (mAb) that recognizes and binds to all major forms of extracellular α-synuclein and thereby intended to prevent uptake and inhibit seeding of aggregation. Amlenetug is being developed by Lundbeck under a joint research and licensing agreement between Lundbeck and Genmab A/S.

About the MASCOT trial
MASCOT (NCT06706622) is a Phase III interventional, randomized, double-blind, parallel-group, placebo-controlled, optional open-label extension trial that will be conducted in North America, Europe, Asia and Australia.3

The trial comprises two parts: A double-blind period where participants are randomized to receive either high or low doses of amlenetug, or placebo for 72 weeks, followed by an open-label extension period where all participants enrolled in the trial are offered treatment with amlenetug. The aim of the trial is to evaluate the efficacy, safety, and tolerability of amlenetug in patients with MSA. Amlenetug is delivered as an intravenous infusion every four weeks.

About Parkinson’s disease
Parkinson’s disease is a progressive and disabling neurological disease characterized by motor symptoms including slowness of movement, tremor and rigidity, as well as a range of non-motor symptoms.4,5

There are currently no established treatments that modify the progression of PD, and levodopa remains a cornerstone of symptomatic treatment.6 With long-term levodopa treatment, many people develop motor complications, including periods when symptoms return or worsen (“OFF-time”) and dyskinesia (involuntary movements), which can significantly affect daily functioning and quality of life.4-7

PD is the second most common neurodegenerative disease after Alzheimer’s disease and the most common movement disorder.7-8 In 2021, an estimated 11.77 million people worldwide were living with PD, and its prevalence is projected to more than double by 2050.9 As PD progresses, functional independence can decline and reliance on caregivers and healthcare systems can increase, contributing to a substantial personal, societal and economic burden.

About Lu AF28996 
Lu AF28996 is an investigational, novel and oral prodrug of a D1-like/D2-like dopamine receptor agonist, with a pharmacologic profile that may enhance dopaminergic striatal signaling in a prolonged manner. It is being investigated for its potential to improve motor fluctuations and levodopa-induced dyskinesia in people with Parkinson’s disease. Concerted activation of D1- and D2-like dopamine receptors may play an important role in motor control.

Lu AF28996 is currently in Phase II clinical development. The DARE2 trial (NCT07514858) is evaluating its efficacy, safety and tolerability in adults with Parkinson’s disease experiencing motor fluctuations despite optimized non-invasive symptomatic treatment.10

Prompts

H. Lundbeck (ticker HLUN-B), listed in Denmark.

ETFs Holding H. Lundbeck

ETF Weight in ETF Shares Market value As of
RGLO 0.21% 111,377 $ 723.257K Jun 30, 2026
DISV 0.21% 1,245,797 $ 10.835M Nov 12, 2026
RINT 0.09% 19,532 $ 126.836K Jun 30, 2026
DFIS 0.07% 437,390 $ 3.804M Nov 12, 2026
GMOI 0.07% 69,120 $ 453.249K Aug 31, 2026
DXIV 0.04% 9,773 $ 84.996K Nov 12, 2026
DFIC 0.03% 479,179 $ 4.167M Nov 12, 2026
DFSI 0.03% 35,256 $ 306.624K Nov 12, 2026
AVSD 0.02% 10,195 $ 91.233K Nov 16, 2026
DFAX 0.02% 248,136 $ 2.158M Nov 12, 2026
DFIV 0.02% 422,143 $ 3.671M Nov 12, 2026
DFAI 0.01% 239,049 $ 2.079M Nov 12, 2026
AVDE 0.01% 128,764 $ 1.151M Nov 16, 2026
AVIV 0.00% 4,214 $ 37.87K Nov 16, 2026

Securities

Ticker Type Class Market Exchange Last price Price date
HLUN-A Common share — DK nordic — —
HLUN-B canonical Common share — DK nordic 60.40 DKK 2026-11-18